Ethylene oxide (EO) gas is commonly used to sterilize medical devices. The amount of residual EO remaining in a device depends partly on the type and size of polymeric material. A major concern is the amount of residue that may be available in the body. With the use of the method described by AAMI for headspace analysis of EO residues, different polymers and medical devices subjected to different numbers of sterilization cycles were examined. Next, the effect of various extraction conditions and extraction solutions on these polymers and medical devices was evaluated. The results showed different polymers desorb EO differently. One polyurethane (PU 75D) had much higher EO residue than a different polyurethane (PU 80A). Repeated extraction of the PU 75D was necessary to quantify total EO residue levels. Different extraction solutions influence the amount and reproducibility of EO detected, whereas multiple resterilizations showed no difference in amount of residual EO. Bioavailability of EO was estimated by extracting the devices and polymers in water. Comparison of total EO residues to EO that was bioavailable showed no difference for some polymers and devices, while others had an almost eightfold difference. Some standard biocompatibility tests were run on extracts and devices, but no significant effects were observed.

ResearchGate Logo

Discover the world's research

  • 20+ million members
  • 135+ million publications
  • 700k+ research projects

Join for free

Residual Ethylene Oxide in Medical Devices and Device Material

Anne D. Lucas, Katharine Merritt, Victoria M. Hitchins, Terry O. Woods, Scott G. McNamee, Dan B. Lyle,

Stanley A. Brown

Center for Devices and Radiological Health, Office of Science and Technology, U.S. Food and Drug Administration

Received 6 November 2002; accepted 8 January 2003

Abstract: Ethylene oxide (EO) gas is commonly used to sterilize medical devices. The

amount of residual EO remaining in a device depends partly on the type and size of polymeric

material. A major concern is the amount of residue that may be available in the body. With

the use of the method described by AAMI for headspace analysis of EO residues, different

polymers and medical devices subjected to different numbers of sterilization cycles were

examined. Next, the effect of various extraction conditions and extraction solutions on these

polymers and medical devices was evaluated. The results showed different polymers desorb

EO differently. One polyurethane (PU 75D) had much higher EO residue than a different

polyurethane (PU 80A). Repeated extraction of the PU 75D was necessary to quantify total EO

residue levels. Different extraction solutions influence the amount and reproducibility of EO

detected, whereas multiple resterilizations showed no difference in amount of residual EO.

Bioavailability of EO was estimated by extracting the devices and polymers in water. Com-

parison of total EO residues to EO that was bioavailable showed no difference for some

polymers and devices, while others had an almost eightfold difference. Some standard bio-

compatibility tests were run on extracts and devices, but no significant effects were observed.

© 2003 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 66B: 548 –552, 2003

Keywords: ethylene oxide; medial device; polymer; bioavailable; toxicity

INTRODUCTION

About 20 –30% of the hospitals in the United States were

formerly reprocessing medical devices.

1

Now there is regu-

latory involvement on the reuse of medical devices, and many

hospitals have left the reprocessing of devices to contractors.

Still, this practice raises many issues, including possible

deleterious effects on the material properties, change in de-

vice performance, and risk of infection. The type of steriliza-

tion method used in reprocessing may have a significant

impact on the performance and safety of a reprocessed and

resterilized device. In the health-care center, one of the more

common ways to sterilize devices is to use ethylene oxide

gas. Ethylene oxide (EO) is used to sterilize medical devices

that cannot be sterilized by heat or radiation. EO sterilization

is relatively inexpensive,

1

but EO and some of its degradation

products are carcinogenic and mutagenic.

2– 4

One question regarding the impact of EO on resterilized

medical devices is the amount of EO residues remaining in a

device following repeated EO resterilizations. EO has been

reported to accumulate in some materials

5

. There are three

residue levels based on exposure categories: limited (daily),

prolonged (monthly), and permanent. Current allowable lim-

its for EO exposure from medical devices are 250 ppm

(recommended level from AAMI TIR 19 as a substitute for

testing for irritation and sensitization), with a daily maximum

human exposure of 20 mg EO for the first day, and 2 mg per

device for frequently used devices.

6,7

These standards have

sections on exhaustive extraction and simulated-use extrac-

tion for EO residues. The standards recommend simulated-

use extraction as the method of choice; however, this is

impractical for devices used for long periods of time, for

example, implants, for which exhaustive extraction is the

usual choice.

To address some of these issues, a series of studies were

conducted to examine residual EO levels in medical devices

and polymers with the use of the method developed by

ANSI/AAMI/ISO

7

for headspace analysis of EO residues.

The effects of various extraction conditions, extraction solu-

tions, and the number of resterilization cycles on the amount

of EO residues were evaluated. In addition, the total amount

of EO, using exhaustive extraction, was compared to the

amount EO that was bioavailable.

8,9

For this study bioavail-

able is defined as the amount of EO that may be assimilated

by the body; this is estimated by extraction of the material or

The opinions or assertions identified by brand name or otherwise are the private

views of the authors and are not to be construed as conveying either an official

endorsement or criticism by the U.S. Department of Health and Human Services or the

Food and Drug Administration.

Correspondence to: Anne D. Lucas, US FDA, CDRH/OST, HFZ 112, 12709

Twinbrook Pkwy, Rockville, MD 20852 (e-mail: adl@cdrh.fda.gov)

© 2003 Wiley Periodicals, Inc.

548

device containing EO in an aqueous solution at 37 °C for

24 h. Following the analytical work, some biocompatibility

tests were conducted on EO sterilized polymers and the

aqueous extracts of EO sterilized devices.

MATERIALS AND METHODS

Materials

Two different polyurethanes, Pellethane 2363-75D (PU 75D)

and 2383-80A (PU 80A), and Nylon 66 were tested. Material

sheets 0.5 mm thick were cut into 10 45-mm strips with

five strips per specimen sample. Two types of electrophysi-

ology diagnostic electrode catheters were also tested. Both

types were from the same manufacturer (Bard), made of

cross-linked polyurethane (personal communication), and ap-

peared to be identical except for the connectors. However,

one catheter had embedded wires (designated solid or S) in

the shaft, whereas the other one was hollow with removable

wires (hollow or H). The wires in the hollow catheter samples

were removed before sterilization. The catheters were cut into

45-mm-long sections with nine sections composing a speci-

men sample.

EO Sterilization

Materials were sterilized on the weekend at the NIH Clinical

Center with the use of 10% EO at 54 °C, 65% RH for 130

min, followed by 12 h aeration at 132 °C. On Monday, after

2 days at room temperature, the samples were retrieved and

stored at 70 °C until prepared for analysis. For resteriliza-

tion studies, samples were left at room temperature for 5 days

before resterilization with EO. Specimens were EO sterilized

0, 1, or 5 times.

Analytical Method

The EO stock standard used in this study was 50 mg/ml in

methanol (Suppelco 4-8838). The standard was then diluted

in water or methanol as needed. EO levels were determined

using the ISO method

7

. Headspace sampling is a method of

introducing volatile components, such as EO, from a liquid or

solid sample into a gas chromatograph. The vial is heated,

allowing the volatile compounds to go into the air (or head-

space) above the liquid or solid sample. After heating, a

gastight syringe is used to remove a portion of the air from

the headspace and inject the sample directly into the gas

chromatograph. A Hewlett-Packard headspace auto sampler

(HP 7694 oven 100 °C, loop 105 °C, vial equilibration time

15– 60 min, pressure: 0.5 min, loop fill: 0.15 min, loop

equilibration time 0.05 min), a HP gas chromatograph 5890

series II (inlet 105 °C, 30 m 0.32 mm Omega-wax 320

capillary column; 30 °C 5 min, 20 °C/min to 100 °C, hold 15

min) and an FID detector (220 °C) were used.

Extraction Method

Samples were analyzed for total EO concentration. Solid

specimens were sealed in a vial and thermally extracted by

heating to 100 °C for 60 min, followed by GC residue

analysis of the headspace gas. Samples were repeatedly

heated and analyzed, with nitrogen purge or evacuation be-

tween cycles, until EO levels approached the limit of reliable

quantitation (approximately 5

g/g).

To evaluate bioavailability of EO residues, water, culture

media [RPMI-1640 with L-glutamine and 10% fetal bovine

serum (FBS)], and cottonseed oil were compared as extrac-

tion solutions. EO was added to each solution (500

g) and

kept at 37 °C for 24 h.

9

The following day, 1-ml aliquots were

removed and analyzed. Based on the results of the three

extraction solutions, water was deemed best, and all of the

materials were subsequently extracted in 13 ml of water for

24 h at 37 °C with 1 ml removed for GC residue analysis. The

hollow and solid catheter pieces used for liquid extraction had

a final surface area to extraction solution volume ratio of 1.96

cm

2

/ml. PU 75D, PU 80A, and Nylon 66 had a 3.5 cm

2

/ml

surface area to volume ratio.

8

Biocompatibility Testing

Apoptosis and Cytotoxicity. In one series of tests, 1 ml

of the water extracts for each material was placed into cell

culture with 2-ml Jurkat cells (a human lymphoma cell,

ATCC CRL 8163) to test viability and appearance of apo-

ptotic cells. In addition, EO standards (final concentration in

cell culture 0.2 to 83

g/ml) were prepared in water and

tested with these cells. Twenty-four hours after adding the

sample or EO standard, an aliquot of the cells was removed

and analyzed using a flow cytometer and LYSIS I-I software

(FACScan, Becton Dickenson, San Jose, CA), as previously

described.

10,11

Cells were analyzed according to the side-

scattering profile (proportional to cellular granularity) verses

the forward-scattering profile (proportional to the cellular

cross sectional area). Changes in the cell populations were

evaluated by gating on the normal cell population and com-

paring to the test groups over time. Apoptotic cells exhibit a

decrease in forward scatter (reduced cell size) and an increase

in side scatter (increased granularity) and can readily be

quantified with the use of a flow cytometer.

10 –13

Cytotoxicity Testing. The polymer PU 75D, which had

the highest EO residue, was tested for its effect on fibroblasts

in culture. EO levels for this particular lot of PU 75 D were

1540.7

g/g EO for exhaustively extracted and 458

g/g in

the water extracts. The protocol was conducted according to

ANSI/AAMI/ISO

14

using extracts and according to ASTM F

813

15

using direct contact tests. The PU 75D samples were

either used immediately after retrieval following the EO

sterilization and aeration protocol (detailed in EO sterilization

section) or were kept frozen at 70 °C until use. The control

PU 75D needed to be sterilized by a means other than EO for

comparison; so control samples were sterilized by autoclav-

ing. Samples were cut to size before the sterilization cycles.

L929 fibroblast cells were grown to a confluent monolayer in

100 15-mm culture dishes with RPMI 1640 medium con-

taining 10% FBS. The medium was removed prior to addition

of the sample or extracts.

549 RESIDUAL ETHYLENE OXIDE IN MEDICAL DEVICES

Direct Contact. The strips of PU 75D (from the same lot

as used in the cytotoxicity testing detailed above) were placed

directly on the cells. Fresh medium was then carefully added

to the dishes. The strips tended to float and those that floated

were carefully submerged with the pipette. The cultures were

examined at 24, 48, and 72 h for evidence of damage to the

cells in the monolayer.

Cytotoxicity of Medium Extracts. For examination of the

effect of extracts, PU 75D samples were placed into RPMI

1640 with FBS for 24 hours at 37 °C. The sample area to

volume ratio was 6 cm

2

/ml. At the end of 24 h, the extract

was withdrawn and placed on the monolayer of cells. The

monolayers were examined at 24, 48, and 72 h for evidence

of cytotoxicity.

Complement Activation. Whole complement activation

was screened in two steps, in accordance with ASTM Stan-

dard Practice F1984-99.

16

Briefly, 0.1 ml of a standard human

complement serum was placed on each of six polymer strips

that had not been exposed to EO, six strips previously ex-

posed to EO (stored at -70 °C until testing), were placed in six

glass tubes on ice, and in six glass tubes to be placed with the

polymer strips in 100% humidity at 37 °C. Following 1 h

incubation, all serum samples were transferred to cold glass

tubes on ice, diluted, and then tested for complement activity

by determining their capacity to lyse sheep red-blood cells

previously coated with a hemolytic antibody (indicated by

cell-free hemoglobin in test supernatant, tested for by absor-

bance at 405 nm).

RESULTS AND DISCUSSION

Resterilization

The amount of EO varied greatly for the different samples.

However, the number of sterilization cycles had little influ-

ence on the amount of EO residuals in the samples studied

(Figure 1).

Exhaustive Extraction

The values in Figure 2 are the cumulative EO values over the

accumulated extraction time. Repeated thermal extraction of

some specimens was necessary to obtain the total amount of

EO. PU 75D had much higher EO residue, while PU 80A had

barely detectable levels (less than 10

g/g, data not shown).

After EO sterilization and aeration, repeated thermal desorp-

tion of some materials was necessary to obtain total EO

residues; the Nylon 66 and PU 75D were thermally extracted

8 times at 60 min at 100 °C to extract most of the EO (Figure

2). PU 75D is harder and more crystalline than PU 80A.

Previous studies of EO residues in polymers demonstrate that

the more crystalline polymer have higher residue,

17–19

poly-

mers with increased chain length desorb EO slower,

19

hard-

ened polymers release EO slowly,

5

while glassy polymers

retain the lowest amounts.

17

Also, highly porous materials

tend to have higher EO values

20

due to low diffusion coef-

ficients and high solubility. Tensile strength testing following

EO sterilization for PU 75D, PU 80A, and Nylon 66 has been

reported.

21

After EO sterilization, PU 75D showed a large

loss of tensile strength, Nylon 66 a small but significant

increase, while PU 80A did not change. These data may

indicate that for those materials that retain larger quantities of

EO, larger changes in material properties, such as strength,

might occur.

The solid and hollow catheter pieces also had significantly

different amounts of residual EO. This was a bit surprising, as

both devices were purchased from the same manufacturer

with the only apparent differences being the connectors and

whether the wires were embedded or removable. The solid

catheter needed to be thermally desorbed repeatedly, just like

Figure 1. Resterilization effect. Materials were resterilized with EO

one (1 ) or five (5 ) times. There was no significant difference in

residue levels between sterilizing once or five times for the polymers

and devices used in this study. PU is polyurethane; N, nylon, S, solid

catheter; H hollow catheters.

Figure 2. Cumulative EO thermally extracted from PU 75D, Nylon 66,

and solid catheter pieces. Samples were thermally extracted eight

times at 60 min at 100 °C then analyzed until EO levels were at the

limit of detection. Both PU 80A and the hollow catheter had very low

levels of EO (less than 10

g/g and 10.4

g/g, respectively; data not

shown).

550 LUCAS ET AL.

the Nylon 66 and the PU 75 D, whereas the hollow catheter

pieces had low EO residues (10.2

g/g).

Extraction Solutions

Figure 3 shows a comparison of three candidate solutions for

extracting EO sterilized medical devices and polymers to

determine residues that are bioavailable. The culture medium

with FBS had much less extractable EO, as the EO probably

reacted with the proteins in the solution (Figure 3). The

control culture medium had some substances that coeluted

with EO. Water and oil did not have any coeluting peaks;

however, the oil presented some significant reproducibility

problems. Because EO is a relatively polar molecule, it did

not dissolve in the oil and was not dispersed uniformly,

resulting in large standard deviations (see Figure 3). Water

showed good reproducibility and a reasonable signal; there-

fore, it was chosen as the extraction solution.

Total EO versus Bioavailable EO. Comparison of EO

residue levels from exhaustive extraction with the levels

obtained from water extraction (Figure 4) illustrates that for

some polymers (Nylon, PU80A, hollow catheters) there is no

significant difference, whereas for others (PU75D, solid cath-

eters) there is up to an eightfold difference. This is likely

related to the microstructure of the polymeric material. Pre-

vious studies have shown that materials with increasing crys-

tallinity will retain more EO, whereas softer flexible materials

will retain less.

17,18

Presumably, the EO retention difference

between the catheters is due to the physical structure. The

hollow catheters had a much larger surface area for EO

diffusion.

Biocompatibility

Apoptosis and Cytotoxicity. No significant difference

was seen between control cells and those with the water

extracts from PU 75D, Nylon 66, PU 80A, or solid or hollow

catheter pieces (data not shown). The current limit for EO

exposure from most medical devices is 250 ppm,

6,7

and even

adding 250

g of the EO standard directly to the cells showed

no changes in viability or number of apoptotic cells. This is

probably due to two factors. First, a cold solution cannot be

added directly to the cells. In warming the water up to room

temperature, EO becomes a gas (boiling point 10.4 °C).

Second, in cell-culture medium, there are large amounts of

proteins, lipids, and other biological molecules in solution.

EO is a reactive alkylating agent; it kills microbes by adding

alkyl groups to DNA, RNA, and proteins. This also makes

EO a toxin for human beings. Before a significant amount of

EO can reach the cells to affect them, most of the EO had

probably reacted first with components in the biological

media.

Direct Contact and Indirect Extraction Assays. For the

PU 75D strips used in these assays, there was an average of

1540.7

g/g EO in the exhaustively extracted sample and 458

g/g EO in water extracts (data not shown). There was no

evidence of damage to the cell monolayer by direct contact

with the EO-sterilized PU 75D strips or by direct contact with

the autoclaved strips. Cells grew up to and onto the strips.

Similarly, the extracts did not cause any damage to the cells.

The extracts themselves were clear, pH did not change, and

they supported cell growth. Previous reports of different

materials have shown a small effect on L929 cells at this

level

22

(agar overlay method).

Complement Assay. Although the PU 75D EO sterilized

strip did activate complement, it was not significantly more

than PU 75D not treated with EO. Although these specific

biocompatibility tests did not generate a positive response,

the toxicity, carcinogenicity, mutagenicity, and teratogenicity

of EO have been well documented.

3

Figure 4. Total EO compared to bioavailable EO. Comparison of the

total amount of thermally extracted EO to that which is bioavailable

(extracted in water). Only PU 75D (a polyurethane) and solid catheter

pieces (solid) showed a significant difference between total EO and

bioavailable EO. PU 75D had approximately 8 times more EO in the

total extract, whereas the solid catheter had 5.5 times more. Nylon 66,

hollow catheter pieces (hollow), and polyurethane 80A (PU80A)

showed no significant differences.

Figure 3. Extraction solution effect. Reproducibility and recovery of

EO (relative to water) in different extraction solutions. 500

g/ml of EO

in cottonseed oil, water, and media were incubated at 37 °C for 24 h,

then analyzed. Media had some coeluting interferences and the oil

had reproducibility problems. Water was used for all subsequent

extractions.

551 RESIDUAL ETHYLENE OXIDE IN MEDICAL DEVICES

CONCLUSIONS

Resterilization with EO has been reported to increase the total

EO residues in some materials

5

. However, for the devices and

polymers used in this study, no significant differences were

seen, even after five resterilization cycles. EO residues in

medical devices and polymers depend on the type and size of

the material. Some materials retain little EO residues, such as

PU 80A and hollow catheters, whereas others retain much

larger amounts, such as PU 75 D and Nylon 66. The choice

of extraction solutions affects the amount of EO detected.

The bioavailability of EO from medical devices and polymers

when compared to the total amount of extractable EO varied

widely. For some materials (PU 75D) EO is much less

extractable in water than was found from exhaustive extrac-

tion (eightfold less). Other polymers (PU 80A, Nylon 66) had

little difference between the amount of total EO and that

which is bioavailable. Adverse bioeffects of EO were not

seen in this study. There was no significant difference be-

tween EO treated PU 75D and untreated PU 75D in comple-

ment activation. Direct and indirect cell culture biocompat-

ibility and viability assays showed no effects. This is possibly

due to a number of factors: (a) EO can diffuse out slowly, (b)

EO reacts with medium components, and (c) EO is a gas at

room temperature (10.4 °C boiling point) and may not even

be in solution for biological testing. However, the toxicity of

EO in vitro and in vivo is well documented.

2– 4

The work presented here illustrates that EO levels and

effects are highly dependent on the type of material used.

Residual EO, the amount of EO that is bioavailable, and the

effect of EO in vitro must be considered for each type of

material or device.

The authors would like to thank Walter Reed Hospital for pro-

viding the catheters and NIH for EO sterilization.

REFERENCES

1. MacNeil JR, Glaser ZR. Comparison of health care-based

sterilization technologies: Safety, efficacy, and economics.

J Healthcare Safety, Compliance & Infection Control 1997;

91–106.

2. International Agency for Research on Cancer. Ethylene Oxide.

IARC monograph on evaluation of carcinogenic risk of chem-

icals to humans; 1985. vol. 36, pp 189 –226.

3. Thier R, Bolt HM. Carcinogenicity and genotoxicity of ethylene

oxide: New aspects and recent advances. Crit Rev Toxicol

2000;30:595– 608.

4. World Health Organization. Ethylene oxide. Environmental

Health Criteria 55, World Health Organization. Geneva: WHO;

1985.

5. Buben I, Melierikoia V, Novona N, Sviakoa R. Problems asso-

ciated with sterilization using ethylene oxide. Residues in

treated materials. Cent Eur J Public Health 1999;7:197–202.

6. Association for the Advancement of Medical Instrumentation.

Technical Information Report 19. Guidance for ANSI/AAMI/

ISO 10993-7: 1995. Biological evaluation of medical devices—

Part 7: Ethylene oxide sterilization residuals. Baltimore, MD:

Association for the Advancement of Medical Instrumentation;

AAMI TIR 19:1998.

7. International Standards Organization. Biological evaluation of

medical devices—Part 7: Ethylene oxide sterilization residuals.

ANSI/AAMI/ISO 10993-7. Baltimore, MD: Association for the

Advancement of Medical Instrumentation; 1995.

8. ASTM Standard Practice F619-02: Standard practice for extrac-

tion of medical plastics. West Conshohocken, PA: American

Society for Testing and Materials; 1997. pp F619 –F679.

9. International Standards Organization. Biological evaluation of

medical devices - Part 12: Sample preparation and reference

materials. ANSI/AAMI/ISO 10993-12. Baltimore, MD: Asso-

ciation for the Advancement of Medical Instrumentation; 1996.

10. Godar DE, Miller SA, Thomas, DP. Immediate and delayed

apoptotic cell death mechanisms: UVA verses UVB and UVC

radiation. Cell Death Differen 1994;1:59 69.

11. Godar DE, Lucas AD. Spectral dependence of UV-induced

immediate and delayed apoptosis: The role of membrane and

DNA damage. Photochem Photobiol 1995;62:108 –113.

12. Dive C, Gregory CD, Phipps DJ, Evans DL, Milner AE, Wyllie

AH. Analysis and discrimination of necrosis and apoptosis

(programmed cell death) by multiparameter flow cytometry.

Biochem Biophys Acta 1992;1133:275–285.

13. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotx

MA, Lassota P, Tranganos F. Features of apoptotic cells mea-

sured by flow cytometry. Cytometry 1992;13:795– 808.

14. International Standards Organization. Biological evaluation of

medical devices—Part 5: Tests for cytotoxicity, in vitro meth-

ods. ANSI/AAMI/ISO 10993-5. Baltimore, MD: Association

for the Advancement of Medical Instrumentation; 1999.

15. ASTM Standard Practice F 813-01: Standard practice for direct

contact cell culture evaluation of materials for medical devices.

Annual Book of ASTM Standards. West Conshohocken, PA:

American Society for Testing and Materials; 2001. vol. 13.01.

16. ASTM Standard Practice F 1984–99: Standard practice for

testing for whole complement activation in serum by solid

materials. Annual Book of ASTM Standards 2001, volume

13.01

17. Gilding, DK, Reed AM, Baskett SA. Ethylene oxide steriliza-

tion: effect of polymer structure and sterilization conditions on

residue levels. Biomat 1980;1:145-148.

18. Vink P, Pleijsier K. Aeration of ethylene oxide-sterilized poly-

mers. Biomat 1986;7:225-230.

19. Guess WL. Residual ethylene oxide and reaction products in

polymers. Bull Parenteral Drug Assoc 1970;24:68 –75.

20. Nair P. Currently practiced sterilization methods—Some inad-

vertent consequences. J Biomater Appl 1995;10:121–135.

21. Brown SA, Merritt K, Woods TO, McNamee SG, Hitchins VM.

Effects of different disinfection and sterilization methods on the

tensile strength of materials used for single-use devices. Biomed

Instrum Tech. 2002;36:23–27.

22. McGunnigle RG, Renner JA, Romano SJ, RA Abodeely. Re-

sidual ethylene oxide: Levels in medical grade tubing and

effects on an in vitro biological system. J Biomed Mater Res

1975;9:273–283.

552 LUCAS ET AL.

... Os dispositivos médicos considerados críticos (aqueles que são introduzidos em áreas estéreis do corpo) e termossensíveis (os que não resistem aos métodos de esterilização a altas temperaturas), para serem reutilizados, necessitam de métodos de esterilização a baixa temperatura, a exemplo da esterilização a óxido de etileno (OE), plasma de peróxido de hidrogênio, vapor de formaldeído e ozônio [8][9] . Entre esses métodos, a esterilização a OE é o mais antigo e considerado padrão-ouro, pela alta difusibilidade e potência do gás esterilizante, contudo é também o mais tóxico dos métodos esterilizantes [8][9][10][11][12][13][14][15][16][17][18][19] . ...

... Os produtos esterilizados pelo OE podem apresentar resíduos tóxicos (etilenocloridrina e etilenoglicol) que, se não removidos, são passíveis de acarretar danos aos pacientes usuários desses produtos, aos profissionais manipuladores e ao meio ambiente. Desse modo, é imperativo que tais PPS sejam submetidos a um processo denominado de "aeração" para remover os resíduos tóxicos [8][9][10][11][12][13][14][15][16][17][18][19][20] . ...

... Nesse sentido, a aeração mecânica, não mencionada por essa norma, constitui o padrão-ouro da aeração de produtos esterilizados por OE, contudo esse processo também requer controles de temperatura e fluxos de ar dentro da câmara Há consenso entre autores de que a duração da aeração depende de fatores já descritos nesta revisão e, entre esses produtos confeccionados à base de cloreto de polivinil (PVC), poliestireno e borrachas são os que mais absorvem OE. Assim, não existe um tempo padrão recomendado para aeração de todos os dispositivos esterilizados por esse agente [8][9][10][11][16][17]20,30,40,23,26,18,35 . ...

  • Eliana Auxiliadora Magalhães Costa

Objetivos: Descrever níveis residuais aceitáveis de óxido de etileno em dispositivos médicos, analisar processos de aeração recomendados e compará-los com a regulaçãobrasileira. Método: Revisão integrativa da literatura, com descritores específicos, sem restrição de ano de publicação. Busca dos dados entre outubro e novembro de 2019,que resultou em 34 estudos incluídos no estudo. Resultados: A regulação brasileira vigente está desatualizada em relação à classificação de produtos, à determinação de valoresde resíduos tóxicos de óxido de etileno em dispositivos médicos e aos processos recomendados para a aeração desses produtos, podendo contribuir para riscos de eventos adversospara pacientes usuários de dispositivos inadequadamente aerados, e, consequentemente, urge sua atualização. Conclusão: As lacunas desse marco regulatório beneficiamindiretamente as empresas que terceirizam a esterilização a óxido de etileno ao omitir controles essenciais para a segurança do paciente exposto a possíveis resíduos tóxicosde óxido de etileno, favorecer práticas inseguras de esterilização de produtos para saúde, além de dificultar o controle de serviço de saúde pelas vigilâncias sanitárias do país.

... While these are widely used techniques, the exploration of possible scaffold damage from these techniques should be investigated. For example, ethanol is drying to the scaffolds and could fracture the intricate tissue structure, while ethylene oxide (EO) has been known to deposit a toxic residue [71]. ...

The decellularization of plant-based biomaterials to generate tissue-engineered substitutes or in vitro cellular models has significantly increased in recent years. These vegetal tissues can be sourced from plant leaves and stems or fruits and vegetables, making them a low-cost, accessible, and sustainable resource from which to generate three-dimensional scaffolds. Each construct is distinct, representing a wide range of architectural and mechanical properties as well as innate vasculature networks. Based on the rapid rise in interest, this review aims to detail the current state of the art and presents the future challenges and perspectives of these unique biomaterials. First, we consider the different existing decellularization techniques, including chemical, detergent-free, enzymatic, and supercritical fluid approaches that are used to generate such scaffolds and examine how these protocols can be selected based on plant cellularity. We next examine strategies for cell seeding onto the plant-derived constructs and the importance of the different functionalization methods used to assist in cell adhesion and promote cell viability. Finally, we discuss how their structural features, such as inherent vasculature, porosity, morphology, and mechanical properties (i.e., stiffness, elasticity, etc.) position plant-based scaffolds as a unique biomaterial and drive their use for specific downstream applications. The main challenges in the field are presented throughout the discussion, and future directions are proposed to help improve the development and use of vegetal constructs in biomedical research.

... For example, γ radiation generates free radicals that can cause tissue damage (Ries et al., 1996;Gorna and Gogolewski, 2003;Mendes et al., 2007). Similarly, ethylene oxide and its derivatives have been reported to accumulate in some materials, potentially increasing teratogenicity risk (Lucas et al., 2003;Mendes et al., 2007). As previously mentioned, the investigator should characterize and validate each sterilization technique for each FSCV sensor type, composition, and geometry to ensure patient safety, in addition to signal accuracy. ...

Fast Scan Cyclic Voltammetry (FSCV) has been used for decades as a neurochemical tool for in vivo detection of phasic changes in electroactive neurotransmitters in animal models. Recently, multiple research groups have initiated human neurochemical studies using FSCV or demonstrated interest in bringing FSCV into clinical use. However, there remain technical challenges that limit clinical implementation of FSCV by creating barriers to appropriate scientific rigor and patient safety. In order to progress with clinical FSCV, these limitations must be first addressed through (1) appropriate pre-clinical studies to ensure accurate measurement of neurotransmitters and (2) the application of a risk management framework to assess patient safety. The intent of this work is to bring awareness of the current issues associated with FSCV to the scientific, engineering, and clinical communities and encourage them to seek solutions or alternatives that ensure data accuracy, rigor and reproducibility, and patient safety.

... Gas sterilization with ethylene oxide was considered, however, we were concerned about toxic residues remaining in the treated material. 35 Heatbased methods for sterilization were deemed inappropriate as our materials were not heat or stream resistant. ...

Scaffold guided breast tissue engineering has the potential to transform reconstructive breast surgery. Currently, there is a deficiency in clinically relevant animal models suitable for studying novel breast tissue engineering concepts. To date, only a small number of large animal studies have been conducted and characterisation of these large animal models is poorly described in the literature. Addressing this gap in the literature, this publication comprehensively describes our original porcine model based on the current published literature and the experience gained from previous animal studies conducted by our research group. In a long-term experiment using our model, we investigated our scaffold guided breast tissue engineering approach by implanting 60 additively manufactured bioresorbable scaffolds under the panniculus carnosus muscle along the flanks of 12 pigs over 12 months. Our model has the flexibility to compare multiple treatment modalities where we successfully investigated scaffolds filled with various treatments of immediate and delayed fat graft and augmentation with platelet rich plasma (PRP). No wound complications were observed using our animal model. We were able to grow clinically relevant volumes of soft tissue, which validates our model. Our preclinical large animal model is ideally suited to assess different scaffold or hydrogel driven soft tissue regeneration strategies.

... Ethylene oxide (EO) is the sterilization technique generally used for polymer-based medical devices, as it can be performed at low-temperatures, which leads to minimal changes in molecular weight compared to other conventional methods [19][20][21]. The major concern with EO sterilization is the presence of toxic residues that can reside on the implant after the process [22][23][24]. In order to remove EO residues such as ethylene glycol and ethylene hydrochloride, an aeration of EO sterilized medical devices must be performed which leads to a lengthening of the final process [25,26]. ...

Although bioabsorbable polymers have garnered increasing attention because of their potential in tissue engineering applications, to our knowledge there are only a few bioabsorbable 3D printed medical devices on the market thus far. In this study, we assessed the processability of medical grade Poly(lactic-co-glycolic) Acid (PLGA)85:15 via two additive manufacturing technologies: Fused Filament Fabrication (FFF) and Direct Pellet Printing (DPP) to highlight the least destructive technology towards PLGA. To quantify PLGA degradation, its molecular weight (gel permeation chromatography (GPC)) as well as its thermal properties (differential scanning calorimetry (DSC)) were evaluated at each processing step, including sterilization with conventional methods (ethylene oxide, gamma, and beta irradiation). Results show that 3D printing of PLGA on a DPP printer significantly decreased the number-average molecular weight (Mn) to the greatest extent (26% Mn loss, p < 0.0001) as it applies a longer residence time and higher shear stress compared to classic FFF (19% Mn loss, p < 0.0001). Among all sterilization methods tested, ethylene oxide seems to be the most appropriate, as it leads to no significant changes in PLGA properties. After sterilization, all samples were considered to be non-toxic, as cell viability was above 70% compared to the control, indicating that this manufacturing route could be used for the development of bioabsorbable medical devices. Based on our observations, we recommend using FFF printing and ethylene oxide sterilization to produce PLGA medical devices.

... Ethylene Oxide (EtO) is known to be a human carcinogen, however, it is commonly used to sterilise medical devices [38]. Contact with the skin, for example, can cause irreversible toxic effects [39]. ...

The current COVID-19 pandemic has resulted in an immense and unforeseen increase in demand for personal protective equipment (PPE) for healthcare workers worldwide. Amongst other products, respirator masks are crucial to protect the users against transmission of the virus. Decontamination and reuse of the existing stock could be a solution to the shortage of new respirators. Based upon existing studies, it was found that (I) a solid quality control method is essential to test product reuse, (II) in-depth evaluation of the different parts of the filtering facepiece respirator (FFR) should be considered, and (III) communication of the reuse cycle is essential to take track of the amount of reuse, as this is limited to ensure quality. The goal of this paper is two-fold. First, we identify the impact of decontamination on the different parts of the FFRs and how the quality control should be performed. Two different types of FFRs are analysed within this paper, resulting in the recommendation of combining quantitative respirator mask fit testing with a thorough sensory evaluation of decontaminated FFRs to qualify them for reuse. Secondly, the possibilities of communication of this reuse to the eventual user are mapped through in-depth reasoning.

... Concern of EtO gas residuals in the scaffolds has always precluded this prospect. Current methods for testing EtO residuals involve extraction in water, so the cytotoxicity elution assay would be an appropriate method to determine the effect of residuals on cell viability 174 . Most importantly, EtO sterilization would substantially simplify the BVM fabrication process; scaffolds could be secured in bioreactors before sterilization, so only media would need to be added to the bioreactors and the flow circuit assembled before starting conditioning. ...

  • Conor Charles Hedigan

Blood vessel mimics (BVMs) are simple tissue engineered blood vessel constructs intended for preclinical testing of vascular devices. This thesis developed and implemented methods to characterize two of these components. The first aim of this thesis investigated the effect of cell culture duration and flow conditions on endothelial cell gene expression, especially regarding endothelial-to-mesenchymal transition (EndMT). A trend of decreased endothelial marker gene expression and increased mesenchymal marker gene expression would indicate EndMT. qPCR analysis revealed that increased cell culture duration did not result in EndMT, and in fact increased endothelial marker expression as cell culture duration increased. Disturbed flow conditions decreased endothelial marker and increased mesenchymal marker expression relative to static culture. The second aim of this thesis developed methods to determine cytotoxicity of, and endothelial cell adhesion to, novel BTEAC salt scaffolds. Immunostaining was used to visualize these scaffold effects. The cytotoxicity elution assay showed that BTEAC salt scaffolds were not more cytotoxic than the standard PLGA scaffold. Direct contact assays spanning several timepoints also found that BTEAC salt scaffolds were not more cytotoxic than standard scaffolds but had higher endothelial cell adhesion and coverage than standard scaffolds. Overall, this thesis developed and implemented methods to characterize the endothelial cells used in the BVM model.

In pathologies of the esophagus such as esophageal atresia, cancers and caustic injuries, methods for full thickness esophageal replacement require the sacrifice of healthy intra-abdominal organs such as the stomach and the colon. These methods are associated with high morbidity, mortality and poor functional results. The reconstruction of an esophageal segment by tissue engineering (TE) could answer this problem. For esophageal TE, this approach has been explored mainly by a combination of matrices and cells. In this chapter, we will discuss the studies on full organ esophageal decellularization, including the animal models, the methods of decellularization and recellularization.

  • Mi Suk Noh
  • Suk Hee Jung
  • Ohryun Kwon
  • Bong-Hyun Jun Bong-Hyun Jun

Hydrogen-peroxide-based low-temperature sterilization is a new sterilization technology for temperature-dependent medical devices. The effect of the process parameters of hydrogen-peroxide-based sterilizer on the sterilization performance of process challenge devices (PCDs) needs to be investigated. Sterilant amount, operating temperature, vacuum pressure, diffusion time, and chamber loading of the sterilizer on the sterilization performance of PCDs were adjusted. Seven PCDs with various morphologies and material containing biological indicators (BI) (EZTest, Geobacillus stearothermophilus) were used to evaluate the sterilization performance. The sterilization success rates of PCDs were 86, 71, and 57% with controlled temperature and pressure, diffusion time, and sterilant volume injection, respectively. The PCD material and structure also obviously affected sterilization performance. The sterilization of PCD A is the least successful for all parameters. Meanwhile, the sterilization of PCD B was influenced by the diffusion time and the sterilant injection volume. PCD B and PCD C were successfully sterilized by controlling the temperature and pressure. The weights and volume of the sterilization loading chamber resulted in a different sterilization performance. Sterilization performances of PCD 1, PCD 2, and PCD 3 were <70, <90, and 100%, respectively. Sterilant volume, sterilant diffusion time, pressure, temperature, PCD types, and chamber loading were proven to be important process parameters of sterilizer that affect the sterilization performance of vaporized-hydrogen-peroxide-based sterilizers.

  • R G Mc Gunnigle
  • J A Renner
  • S J Romano
  • R. A. Abodeely

The level of residual ethylene oxide after sterilization was evaluated as a function of aeration time for three medical grade tubings. Toxicity resulting from residual ethylene oxide was determined in an in vitro tissue culture system utilizing L-cells. The absorption and desorption of ethylene oxide from poly(vinyl chloride) and polyether-polyurethane tubing were similar. In contrast, silicone tubing absorbed 85% less ethylene oxide. The time required for desorption of residual ethylene oxide was 2 hr for silicone tubing and 7 to 8 hr for poly(vinyl chloride) and polyether-polyurethane tubing. Tubing samples containing 1,500 ppm or more residual ethylene oxide elicited toxic tissue culture reactions whereas samples containing 900 ppm or less showed no toxic tissue culture response.

  • Zbigniew Darzynkiewicz Zbigniew Darzynkiewicz
  • Bruno SG
  • G Del Bino
  • F Traganos

The present review describes several methods to characterize and differentiate between two different mechanisms of cell death, apoptosis and necrosis. Most of these methods were applied to studies of apoptosis triggered in the human leukemic HL-60 cell line by DNA topoisomerase I or II inhibitors, and in rat thymocytes by either topoisomerase inhibitors or prednisolone. In most cases, apoptosis was selective to cells in a particular phase of the cell cycle: only S-phase HL-60 cells and G0 thymocytes were mainly affected. Necrosis was induced by excessively high concentrations of these drugs. The following cell features were found useful to characterize the mode of cell death: a) Activation of an endonuclease in apoptocic cells resulted in extraction of the low molecular weight DNA following cell permeabilization, which, in turn, led to their decreased stainability with DNA-specific fluorochromes. Measurements of DNA content made it possible to identify apoptotic cells and to recognize the cell cycle phase specificity of the apoptotic process. b) Plasma membrane integrity, which is lost in necrotic but not apoptotic cells, was probed by the exclusion of propidium iodide (PI). The combination of PI followed by Hoechst 33342 proved to be an excellent probe to distinguish live, necrotic, early- and late-apoptotic cells. c) Mitochondrial transmembrane potential, assayed by retention of rhodamine 123 was preserved in apoptotic but not necrotic cells. d) The ATP-dependent lysosomal proton pump, tested by the supravital uptake of acridine orange (AO) was also preserved in apoptotic but not necrotic cells. e) Bivariate analysis of cells stained for DNA and protein revealed markedly diminished protein content in apoptotic cells, most likely due to activation of endogenous proteases. Necrotic cells, having leaky membranes, had minimal protein content. f) Staining of RNA allowed for the discrimination of G0 from G1 cells and thus made it possible to reveal that apoptosis was selective to G0 thymocytes. g) The decrease in forward light scatter, paralleled either by no change (HL-60 cells) or an increase (thymocytes) of right angle scatter, were early changes during apoptosis. h) The sensitivity of DNA in situ to denaturation, was increased in apoptotic and necrotic cells. This feature, probed by staining with AO at low pH, provided a sensitive and early assay to discriminate between live, apoptotic and necrotic cells, and to evaluate the cell cycle phase specificity of these processes. i) The in situ nick translation assay employing labeled triphosphonucleotides can be used to reveal DNA strand breaks, to detect the very early stages of apoptosis.(ABSTRACT TRUNCATED AT 400 WORDS)

  • Caroline Dive
  • Chris Gregory Chris Gregory
  • Donna J. Phipps
  • AH Wyllie

Necrosis and apoptosis are two distinct modes of cell death which differ in morphology, mechanism and incidence. Membrane disruptants, respiratory poisons and hypoxia cause ATP depletion, metabolic collapse, cell swelling and rupture leading to inflammation. These are typical features of necrosis. Apoptosis plays a crucial role in embryogenesis and development and is also prevalent in tumours. It is characterised by cell shrinkage, chromatin condensation and systematic DNA cleavage. Apoptotic cells are rapidly engulfed by phagocytes, thus preventing inflammatory reaction to degradative cell contents. In vivo, apoptosis is almost impossible to quantify due to problems of heterogeneity and the short half-life of an apoptotic cell. In vitro, mechanistic studies are further complicated by a late phase of apoptosis where the cell membrane becomes permeable to vital dyes and which occurs in the absence of phagocytes. Here we describe a novel and rapid multiparameter flow cytometric assay which discriminates and quantifies viable, apoptotic and necrotic cells via measurement of forward and side light scatter (proportional to cell diameter and internal granularity, respectively) and the DNA-binding fluorophores Hoechst 33342 and propidium. It is anticipated that mechanistic studies of apoptosis in a variety of cell types will greatly benefit from this mode of analysis.

  • P Vink
  • K Pleijsier

The ethylene oxide (EO) content of 17 polymers sterilized with 100% EO under conditions normally used in practice was determined as a function of aeration time, and for some polymers also as a function of sample thickness. The determination of the amount of residual EO has been carried out by gas chromatography, applying Discontinuous Gas Extraction and Head Space analysis. Generally, aeration was confirmed to be a diffusion-controlled process. Diffusion coefficients of EO for the investigated materials were determined from the rates of desorption. For a number of materials the EO content appeared to be well above the levels for EO which currently are considered to be safe, even after aeration for 15 d. For a reliable determination of aeration times required for EO-sterilized medical devices, the type and in particular also the thickness of the material from which the device is made should be considered.

The phototoxicity of each waveband region of UV radiation (UVR), i.e., UVA (320-400 nm), UVB (290-320 nm) and UVC (200-290 nm), was correlated with an apoptotic mechanism using equilethal doses (10% survival) on murine lymphoma L5178Y-R cells. Apoptosis was qualitatively monitored for DNA "ladder" formation (multiples of 200 base pair units) using agarose gel electrophoresis, while the percentages of apoptotic and membrane-permeabilized cells were quantified over a postexposure time course using flow cytometry. The UVA1 radiation (340-400 nm) induced both an immediate (< 4 h) and a delayed (> 20 h) apoptotic mechanism, while UVB or UVC radiation induced only the delayed mechanism. The role of membrane damage was examined using a lipophilic free-radical scavenger, vitamin E. Immediate apoptosis and membrane permeability increased in a UVA1 dose-dependent manner, both of which were reduced by vitamin E. However, vitamin E had little effect on UVR-induced delayed apoptosis. In contrast, the DNA damaging agents 2,4- and 2,6-diaminotoluene exclusively induced delayed apoptosis. Thus, immediate apoptosis can be initiated by UVA1-induced membrane damage, while delayed apoptosis can be initiated by DNA damage. Moreover, the results suggest that immediate and delayed apoptosis are two independent mechanisms that exist beyond the realm of photobiology.

  • Prabha Damodaran Nair Prabha Damodaran Nair

Currently used sterilization techniques such as ethylene oxide, gamma irradiation, and steam sterilization could introduce inadvertent consequences, especially in polymeric materials. These could have far-reaching effects on the biocompatibility of the materials. Some of these consequences are reviewed and a typical example of the effect of steam sterilization on the properties and biocompatibility of polyethylene terephthalate is discussed.

  • I. Buben
  • V. Melicherčíková
  • N. Novotná
  • R. Svitáková

The paper deals with problems associated with reduction of undesirable effects of ethylene oxide in polymers in medical devices on the patient's health. The authors explain the need of careful elaboration and validation of the sterilization and aeration process incl assessment of ethylene oxide (EO) residues. The authors investigated the effect of the type of material and conditions of sterilization and aeration on the assessed EO concentration. For research of the behaviour of different polymers in the sterilization process model sterilizations of actual items of medical devices with a known composition proved more suitable than assessment in medical devices from medical institutions. The main conclusions of the investigation were a classification of polymers into those suitable and unsuitable for sterilization or resterilization, and attention was also drawn to poor reproducibility of results in old sterilizers, in particular those lacking effective aeration in aerators.